Clinical Trial

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-12-11; most recent amendment 2025-09-09.
Status change: Active, Not Recruiting → Recruiting 2023-09-10
Status change: Recruiting → Active, Not Recruiting 2022-05-24
Trial Details
NCT Number NCT03774446
Lead Sponsor Cedars-Sinai Medical Center
Conditions Cushing Disease
Enrollment 13 participants
Start Date 2018-11-02
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-11